Researchers have identified chromosomal instability in circulating tumour cells as a prognostic and predictive biomarker in ...

Tukysa (tucatinib) may represent a new patient-friendly option as a first line maintenance treatment possibility for patients ...

Clinicians treating patients with estrogen receptor (ER)-positive/HER2-negative metastatic breast cancer are navigating ...

At the San Antonio Breast Cancer Symposium (SABCS), investigators outlined the rationale and design of the ERADICATE, a first ...

HER2CLIMB-05 trial evaluated Tukysa in combination with Herceptin and Perjeta for HER2-positive metastatic breast cancer, ...

The key drivers of increased investor interest in AstraZeneca are the strong performance of its oncology and cardiovascular ...

Radiopharmaceutical therapy (RPT) combined with external beam radiotherapy (EBRT) is emerging as a powerful approach in prostate cancer treatment. Historically rooted in early 89Sr trials, this ...

In the PREFER trial, researchers aimed to investigate and assess the safety of strategies for fertility preservation in ...

The HER2CLIMB-05 study assessed the efficacy and safety of adding tucatinib to maintenance therapy with trastuzumab/pertuzumab in patients with HER2+ metastatic breast cancer.

Prostate cancer is highly treatable when detected early, as it carries a favourable prognosis. Therefore, awareness among ...

Patients should be selected for treatment with Enhertu in combination with pertuzumab based on confirmed HER2-positive status or HER2 gene amplification (IHC 3+ or ISH+).

Glomus tumours are uncommon, typically benign neoplasms of specialised dermal thermoregulatory structures known as glomus ...